Cimlanod Inhibitor

Cimlanod is a second-generation Nitroxyl (HNO) donor for heart failure with positive lusitropic and inotropic as well as vasodilatory effects. Cimlanod delivers HNO via pH-dependent chemical breakdown when exposed to the neutral pH environment of the bloodstream.

Cowart D, et al. A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers. J Clin Pharmacol. 2019 May;59(5):717-730.
Cowart D, et al. A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers. J Clin Pharmacol. 2019 May;59(5):717-730.
Felker GM, et al. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. Eur J Heart Fail. 2019 Aug;21(8):1022-1031.
Felker GM, et al. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. Eur J Heart Fail. 2019 Aug;21(8):1022-1031.

Small volumes of Cimlanod, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5754717 is an inhibitor targeting Cimlanod.